Bedell Frazier Investment Counselling LLC Has $5.06 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bedell Frazier Investment Counselling LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,813 shares of the biopharmaceutical company’s stock after selling 41 shares during the quarter. Bedell Frazier Investment Counselling LLC’s holdings in Regeneron Pharmaceuticals were worth $5,060,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC lifted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after buying an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after purchasing an additional 59,769 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after buying an additional 82,034 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of REGN opened at $738.00 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $81.10 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 2.84 and a beta of 0.15. The stock’s 50-day moving average price is $945.07 and its 200-day moving average price is $1,027.53.

Analysts Set New Price Targets

Several research firms recently weighed in on REGN. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Citigroup initiated coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective for the company. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.